Research Projects

Outcome-related projects:

  • A critical appraisal of drug-drug interaction databases
  • A prospective multicenter cohort study evaluating the characteristics and clinical implications of a clinical decision support system and of pharmacogenomic information relevant to polypharmacy actions in patients with advanced illness who are receiving multiple drugs for pain or other diseases
  • An observational exploration of various medication risk scores calculated from electronic health record data in a general population and correlated with medical outcomes
  • Predictive value of MedWise Risk Score™ and pharmacogenomics on health outcomes in patients with type 2 diabetes
  • Evaluating the impact of CYP2D6 guided opioid therapy on pain management in a Program of All-Inclusive Care for the Elderly (PACE) setting
  • An observational study of drug-drug interactions involving CYP2D6 among chronic opioid users and their potential impact on healthcare costs
  • An observational exploration of various medication risk scores as a predictive value of adverse drug event: Development and validation of a dose-sensitive anticholinergic and sedative composite risk score
  • Investigating the impact of SARS-CoV-2 on pharmacy personnel and sleep quality
  • Evaluating patient no-show rates during a pandemic
  • Investigating changes to Medicaid telehealth reimbursement policies during a pandemic
  • Predicting adverse drug events, hospitalizations, and emergency department visits in PACE: A comparison of the MedWise Risk Score and hierarchical condition category scores
  • The clinical effectiveness of pharmacist-driven medication reviews in PACE
  • The clinical effectiveness of pharmacist-driven medication reviews in EMTM
  • Investigating pharmacy technician perspective of an enhanced medication reconciliation protocol in a national Medication Therapy Management call center setting
  • Comparing the predictive strength of the LACE+ Index with the MedWise Rise Score on hospital readmission rates: A non-inferiority observational study
  • Identifying the effects of drug pricing and cost barriers on medication adherence
  • Comprehensive Medication Review completion rates in medically underserved areas and populations
  • Assessment of medication prescribing and adherence in older adults with asthma and chronic obstructive pulmonary disease
  • Impact of pharmacist-driven Medication Safety Reviews™ and polypharmacy calls in the Program of All-Inclusive Care for the Elderly (PACE) setting
  • Human on a chip evaluation of drug-drug interactions associated with COVID-19 therapeutics for an at-risk population

Product-related projects:

  • Torsadogenic risk evaluation of physiological and supraphysiological medication dosing
  • Evaluating community pharmacy staff perception of a clinical decision support system
  • Pharmacometrics modeling and simulation of probe drug profiles subjected to competitive inhibition under various drug administration conditions
  • Implementation of a pharmacist-driven antipsychotic deprescribing initiative in the Program of All-Inclusive Care for the Elderly (PACE) setting: A pilot study
  • Effect of concierge pharmacist services on provider burnout
  • PACE organization attributes associated with economic and clinical outcomes
  • Modulatory role of blood-brain-barrier and enzymatic activity in an innovative human model of cholinergic drug induced dementia
  • Impact of low level chronic systemic inflammation on Alzheimer’s drug disposition and action
  • Simulation of risk of adverse drug events associated with the initiation of drugs repurposed for the treatment of SARS-CoV-2 in adults with polypharmacy using data from large Medicare and commercially insured populations
  • Evaluating the impact of pharmacist-delivered Comprehensive Medication Reviews on National Quality Forum and consumer assessment of healthcare providers and systems scores in a hospice setting
  • Exploring the impact of MedWise service integration on readmission rates within the Discharge Companion Program
  • Reduction in anticholinergic burden related to bladder antimuscarinics for patients in a Program of All-Inclusive Care for the Elderly (PACE) setting
  • Assessment of SOAP notes to characterize the impact of pharmacist’s interventions with a Comprehensive Medication Review
  • Identifying and reducing the risks associated with chronic opioid use among older Medicare adults
  • Evaluating the impact of novel medication adherence interventions on the proportion of days covered rate
  • Assessment of clinical outcomes following a pharmacist-delivered Comprehensive Medication Review for patients with type 2 diabetes and dyslipidemia
  • Assessment of mortality rates in SARS-CoV-2 infected populations treated with repurposed medications
  • Evaluating medication risk management program outcomes and efficiencies
  • Exploring the value of an outcomes dashboard
  • Exploration of PACE value
  • Assessing the potential value of preemptive pharmacogenetic testing in a PACE setting